Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Female
Humans
Male
Class I Phosphatidylinositol 3-Kinases
/ genetics
High-Throughput Nucleotide Sequencing
Klippel-Trenaunay-Weber Syndrome
/ genetics
Phosphatidylinositol 3-Kinases
/ genetics
Proto-Oncogene Proteins c-akt
/ genetics
TOR Serine-Threonine Kinases
Child, Preschool
Child
Adolescent
Young Adult
Adult
Middle Aged
Capillary malformations
High-throughput nucleotide sequencing
Klippel–Trenaunay Syndrome
Limb hypertrophy
Lymphatic abnormalities
PIK3CA-related overgrowth spectrum
Phosphatidylinositol 3-Kinase
Segmental hypertrophy
Vascular malformations
Venous malformations
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
04 09 2023
04 09 2023
Historique:
received:
19
04
2023
accepted:
26
08
2023
medline:
6
9
2023
pubmed:
5
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Klippel-Trenaunay syndrome (KTS) is a rare slow-flow combined vascular malformation with limb hypertrophy. KTS is thought to lie on the PIK3CA-related overgrowth spectrum, but reports are limited. PIK3CA encodes p110α, a catalytic subunit of phosphatidylinositol 3-kinase (PI3K) that plays an essential role in the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway. We aimed to demonstrate the clinical utility of targeted next-generation sequencing (NGS) in identifying PIK3CA mosaicism in archival formalin-fixed paraffin-embedded (FFPE) tissues from patients with KTS. Participants were 9 female and 5 male patients with KTS diagnosed as capillaro-venous malformation (CVM) or capillaro-lymphatico-venous malformation (CLVM). Median age at resection was 14 years (range, 5-57 years). Median archival period before DNA extraction from FFPE tissues was 5.4 years (range, 3-7 years). NGS-based sequencing of PIK3CA achieved an amplicon mean coverage of 119,000x. PIK3CA missense mutations were found in 12 of 14 patients (85.7%; 6/8 CVM and 6/6 CLVM), with 8 patients showing the hotspot variants E542K, E545K, H1047R, and H1047L. The non-hotspot PIK3CA variants C420R, Q546K, and Q546R were identified in 4 patients. Overall, the mean variant allele frequency for identified PIK3CA variants was 6.9% (range, 1.6-17.4%). All patients with geographic capillary malformation, histopathological lymphatic malformation or macrodactyly of the foot had PIK3CA variants. No genotype-phenotype association between hotspot and non-hotspot PIK3CA variants was found. Histologically, the vessels and adipose tissues of the lesions showed phosphorylation of the proteins in the PI3K/AKT/mTOR signaling pathway, including p-AKT, p-mTOR, and p-4EBP1. The PI3K/AKT/mTOR pathway in mesenchymal tissues was activated in patients with KTS. Amplicon-based targeted NGS could identify low-level mosaicism from low-input DNA extracted from FFPE tissues, potentially providing a diagnostic option for personalized medicine with inhibitors of the PI3K/AKT/mTOR signaling pathway.
Sections du résumé
BACKGROUND
Klippel-Trenaunay syndrome (KTS) is a rare slow-flow combined vascular malformation with limb hypertrophy. KTS is thought to lie on the PIK3CA-related overgrowth spectrum, but reports are limited. PIK3CA encodes p110α, a catalytic subunit of phosphatidylinositol 3-kinase (PI3K) that plays an essential role in the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway. We aimed to demonstrate the clinical utility of targeted next-generation sequencing (NGS) in identifying PIK3CA mosaicism in archival formalin-fixed paraffin-embedded (FFPE) tissues from patients with KTS.
RESULTS
Participants were 9 female and 5 male patients with KTS diagnosed as capillaro-venous malformation (CVM) or capillaro-lymphatico-venous malformation (CLVM). Median age at resection was 14 years (range, 5-57 years). Median archival period before DNA extraction from FFPE tissues was 5.4 years (range, 3-7 years). NGS-based sequencing of PIK3CA achieved an amplicon mean coverage of 119,000x. PIK3CA missense mutations were found in 12 of 14 patients (85.7%; 6/8 CVM and 6/6 CLVM), with 8 patients showing the hotspot variants E542K, E545K, H1047R, and H1047L. The non-hotspot PIK3CA variants C420R, Q546K, and Q546R were identified in 4 patients. Overall, the mean variant allele frequency for identified PIK3CA variants was 6.9% (range, 1.6-17.4%). All patients with geographic capillary malformation, histopathological lymphatic malformation or macrodactyly of the foot had PIK3CA variants. No genotype-phenotype association between hotspot and non-hotspot PIK3CA variants was found. Histologically, the vessels and adipose tissues of the lesions showed phosphorylation of the proteins in the PI3K/AKT/mTOR signaling pathway, including p-AKT, p-mTOR, and p-4EBP1.
CONCLUSIONS
The PI3K/AKT/mTOR pathway in mesenchymal tissues was activated in patients with KTS. Amplicon-based targeted NGS could identify low-level mosaicism from low-input DNA extracted from FFPE tissues, potentially providing a diagnostic option for personalized medicine with inhibitors of the PI3K/AKT/mTOR signaling pathway.
Identifiants
pubmed: 37667289
doi: 10.1186/s13023-023-02893-1
pii: 10.1186/s13023-023-02893-1
pmc: PMC10478188
doi:
Substances chimiques
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
PIK3CA protein, human
EC 2.7.1.137
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
270Informations de copyright
© 2023. Institut National de la Santé et de la Recherche Médicale (INSERM).
Références
Vascular. 2021 Feb;29(1):85-91
pubmed: 32588787
Genet Med. 2021 Dec;23(12):2433-2442
pubmed: 34385668
Diagn Pathol. 2020 Jul 25;15(1):98
pubmed: 32711543
Br J Cancer. 2022 Feb;126(3):456-463
pubmed: 34754095
Am J Med Genet A. 2018 Nov;176(11):2301-2308
pubmed: 30063105
Orphanet J Rare Dis. 2020 Aug 10;15(1):205
pubmed: 32778138
Orphanet J Rare Dis. 2021 Feb 27;16(1):109
pubmed: 33639990
Genet Med. 2021 Jan;23(1):123-130
pubmed: 32884133
Nat Genet. 2012 Jun 24;44(8):934-40
pubmed: 22729224
Trends Mol Med. 2018 Oct;24(10):856-870
pubmed: 30197175
PLoS One. 2015 Apr 27;10(4):e0123092
pubmed: 25915946
Orphanet J Rare Dis. 2020 Oct 14;15(1):288
pubmed: 33054853
J Invest Dermatol. 2018 Apr;138(4):957-967
pubmed: 29174369
J Invest Dermatol. 2016 Jan;136(1):15-23
pubmed: 26763419
JCI Insight. 2016 Jun 16;1(9):
pubmed: 27631024
Am J Med Genet A. 2020 Jan;182(1):162-168
pubmed: 31729162
Cell Cycle. 2004 Oct;3(10):1221-4
pubmed: 15467468
J Clin Invest. 2014 Mar;124(3):898-904
pubmed: 24590274
Clin Chem. 2015 Jan;61(1):64-71
pubmed: 25421801
J Hand Surg Eur Vol. 2018 Sep;43(7):756-760
pubmed: 29661094
Orphanet J Rare Dis. 2021 Jul 8;16(1):306
pubmed: 34238334
Nature. 2008 May 29;453(7195):662-6
pubmed: 18449193
Angiogenesis. 2017 Aug;20(3):303-306
pubmed: 28120216
Clin Genet. 2021 May;99(5):650-661
pubmed: 33415748
Nat Genet. 2012 Jun 24;44(8):928-33
pubmed: 22729222
Clin Genet. 2017 Jan;91(1):79-85
pubmed: 27307077
Science. 2007 Dec 14;318(5857):1744-8
pubmed: 18079394
Angiogenesis. 2020 Aug;23(3):425-442
pubmed: 32350708
Pediatr Neurol. 2021 Jan;114:55-59
pubmed: 33221597
Plast Reconstr Surg. 2011 Jan;127(1):340-346
pubmed: 21200228
JCI Insight. 2019 Nov 1;4(21):
pubmed: 31536475
Pediatr Dermatol. 2013 Sep-Oct;30(5):541-8
pubmed: 23829172
Eur J Endocrinol. 2017 Aug;177(2):175-186
pubmed: 28566443
Mod Pathol. 2020 Mar;33(3):420-430
pubmed: 31481664
Cell Rep. 2015 Mar 17;10(10):1708-1721
pubmed: 25772358
Genet Med. 2019 May;21(5):1189-1198
pubmed: 30270358
Adv Wound Care (New Rochelle). 2019 Jun 1;8(6):246-255
pubmed: 31832274
J Med Genet. 2023 Feb;60(2):163-173
pubmed: 35256403
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
Am J Med Genet A. 2014 Jul;164A(7):1713-33
pubmed: 24782230
Clin Cancer Res. 2021 Apr 1;27(7):1842-1849
pubmed: 33168657
J Mol Diagn. 2017 Jul;19(4):613-624
pubmed: 28502725
Plast Reconstr Surg. 2014 Jan;133(1):12e-19e
pubmed: 24374682
Nat Genet. 2009 Jan;41(1):118-24
pubmed: 19079259
Genet Med. 2017 Sep;19(9):989-997
pubmed: 28151489
Curr Opin Hematol. 2019 May;26(3):170-178
pubmed: 30855339
Am J Med Genet A. 2022 Jun;188(6):1792-1800
pubmed: 35238469
Orphanet J Rare Dis. 2021 May 8;16(1):208
pubmed: 33964933
J Pediatr. 2015 Apr;166(4):1048-54.e1-5
pubmed: 25681199
PLoS One. 2019 Apr 11;14(4):e0211400
pubmed: 30973937
HGG Adv. 2022 Mar 15;3(2):100101
pubmed: 35373151
Am J Med Genet A. 2015 Feb;167A(2):287-95
pubmed: 25557259
Mol Genet Genomic Med. 2019 Mar;7(3):e536
pubmed: 30761771
Hum Mol Genet. 2013 Feb 1;22(3):444-51
pubmed: 23100325
Genes Chromosomes Cancer. 2019 Aug;58(8):541-550
pubmed: 30677207
Clin Genet. 2018 May;93(5):1075-1080
pubmed: 29231959
Am J Hum Genet. 2012 Jun 8;90(6):1108-15
pubmed: 22658544
Nature. 2018 Jun;558(7711):540-546
pubmed: 29899452
Am J Hum Genet. 2015 Dec 3;97(6):914-21
pubmed: 26637981
Orphanet J Rare Dis. 2021 Jun 10;16(1):267
pubmed: 34112235
Am J Med Genet A. 2017 Apr;173(4):978-984
pubmed: 28328134
Exp Dermatol. 2016 Jan;25(1):17-9
pubmed: 26268729
J Hum Genet. 2022 Dec;67(12):721-728
pubmed: 36171295
J Dermatol. 2019 Nov;46(11):e403-e405
pubmed: 31281999
Angiogenesis. 2015 Apr;18(2):151-62
pubmed: 25424831
J Am Acad Dermatol. 2004 Sep;51(3):391-8
pubmed: 15337982
Orphanet J Rare Dis. 2018 Oct 29;13(1):191
pubmed: 30373605